News about Market

US FDA Approves Uplizna for Adults with Generalised Myasthenia Gravis

The US FDA has approved Uplizna for adults with generalised myasthenia gravis, marking a significant advancement as the first and only CD19-targeted B-cell therapy for both anti-AChR and anti-MuSK antibody–positive patients, offering durable disease control with just twice-yearly dosing.

Market | 12/12/2025 | By Akanki |  142

Cycle Pharmaceuticals to Acquire Applied Therapeutics

The acquisition positions Cycle Pharmaceuticals to strengthen its rare disease portfolio, adding Applied Therapeutics’ promising CNS-penetrant aldose reductase inhibitor, govorestat, which targets severe unmet needs in central nervous system metabolic disorders.

Market | 12/12/2025 | By Akanki |  213

D3 Bio Secures USD 108 Million in Series B Financing to Advance Global Clinical Programmes

D3 Bio has raised USD 108 million in Series B financing to advance its global clinical programmes. The funds will support the Phase III pivotal trial of its lead asset, elisrasib (D3S-001), while also accelerating the development of the company’s broader pipeline of targeted and immuno-oncology therapies with first-in-class and best-in-class potential.

Market | 11/12/2025 | By Akanki |  211

Novo Nordisk Completes Acquisition of Akero Therapeutics

Novo Nordisk has finalised its acquisition of Akero Therapeutics, making Akero a wholly owned subsidiary. Following the transaction, Akero’s common stock will cease trading on the Nasdaq Global Select Market.

Market | 10/12/2025 | By Akanki |  247

Terns Prices Upsized USD 650 Million Public Offering

Terns plans to use the proceeds to advance research and clinical development of its pipeline, including TERN-701, support early commercial launch preparations, and fund working capital and general corporate needs.

Market | 10/12/2025 | By Akanki |  167

Yao Pharma and Pfizer Sign Exclusive Collaboration Deal

Yao Pharma has entered into an exclusive global licensing agreement with Pfizer, granting rights to develop, manufacture, and commercialise its oral small-molecule GLP-1 receptor agonists, including lead candidate YP05002. The partnership aims to advance next-generation metabolic therapies with worldwide reach.

Market | 10/12/2025 | By Akanki |  132

Hikma Launches TYZAVAN in US

Hikma has launched TYZAVAN in the US, introducing a glycopeptide antibacterial in pre-filled, ready-to-use bags designed to streamline hospital workflows and support faster and safer treatment.

Market | 09/12/2025 | By Akanki |  167

Covestro and Allmed Partner to Recycle Artificial Kidney Filters

Covestro and Allmed have launched a feasibility study to explore recycling pathways for artificial kidney filters, bringing together Kimal, hospitals, and recycling partners to build a full medical plastics recycling ecosystem.

Market | 09/12/2025 | By Akanki |  136

L'Oreal to Double Its Equity Stake in Galderma as Strategic Partnership Deepens

Galderma Group AG, the pure-play leader in the dermatology category, announced that L’Oréal Groupe plans to increase its equity investment in the company by acquiring an additional 10 percent stake from Sunshine SwissCo GmbH, a consortium led by EQT, the Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd. as the sellers.

Market | 09/12/2025 | By Darshana |  257

Convergen Raises USD 10 Million Seed Funding to Advance TrimTAC Platform

Convergen has raised USD 10 million in seed funding from Qiming Venture Partners to speed up development of its TrimTAC platform—novel TRIM21-based bifunctional degraders—and advance its early pipeline targeting neurodegenerative and other high-need diseases.

Market | 09/12/2025 | By Akanki |  173